Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001144204-10-028799)

Filing Details

Accession Number:: 0001144204-10-028799
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-05-18 13:00:00
Reporting Period:: 2010-05-17

Filing Date:: 2010-05-18
Accepted Time:: 2010-05-18 16:08:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1318641	Cleveland Biolabs Inc	CBLI	Services-Commercial Physical & Biological Research (8731)	200077155

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1370083	V Andrei Gudkov	73 High Street Buffalo NY 14203	Chief Scientific Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2010-05-17	200	$3.52	1,509,400	No	4	S	Direct
Common Stock	Disposition	2010-05-17	3,010	$3.50	1,506,390	No	4	S	Direct
Common Stock	Disposition	2010-05-17	900	$3.60	1,505,490	No	4	S	Direct
Common Stock	Disposition	2010-05-17	300	$3.62	1,505,190	No	4	S	Direct
Common Stock	Disposition	2010-05-17	290	$3.51	1,504,900	No	4	S	Direct
Common Stock	Disposition	2010-05-17	100	$3.56	1,504,800	No	4	S	Direct
Common Stock	Disposition	2010-05-17	200	$3.53	1,504,600	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Employee Stock Options (Right to Buy)	$8.36	2007-04-06	2017-04-05	37,500	37,500	Direct
Common Stock	Employee Stock Options (Right to Buy)	$4.00	2008-02-04	2018-02-03	137,250	137,250	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2017-04-05	37,500	37,500	Direct
2018-02-03	137,250	137,250	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan and represent approximately 0.3% of the reporting person's 1,549,600 shares held prior to adoption of the plan. The maximum sales subject to the plan in its entirety represent approximately 3.9% of the reporting person's shares held prior to adoption of the plan.